Mainstream

Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO

Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO

Post ContentlbrxRead More

You might also be interested in reading ECB Sets Cautious Path for Tokenized Capital Markets in New Bulletin.

September 9, 2025
In Mainstream